Steven Standaert, MD
Infectious Disease · Olympia, WANPI 1750455317
Payments from drug & device makers
What this record shows
Almost everything reported here is food and beverage — 100.0% of the total across 1 separate payments, which is the pattern of a clinician who attends manufacturer presentations rather than one with a consulting arrangement. Every reported general payment came from a single manufacturer, Ferring Pharmaceuticals Inc..
Across 1 payment — averaging $123.74 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Ferring Pharmaceuticals Inc.$124
Across 13 payments — averaging $32,914 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Astrazeneca UK Limited$270K
- Gilead$158K
What the payments were for
- Food & beverage$124100%
Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Ferring Pharmaceuticals Inc. | 1 | $124 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
- REBYOTA$124
How this compares
$124 in reported general payments places this provider in the 55th percentile of 186 infectious disease providers in Washington.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BiktarvyBictegrav/Emtricit/Tenofov Ala | 107 | $467,620 |
| TriumeqAbacavir/Dolutegravir/Lamivudi | 107 | $418,334 |
| GenvoyaElviteg/Cob/Emtri/Tenof Alafen | 48 | $190,426 |
| OdefseyEmtricitab/Rilpiviri/Tenof Ala | 18 | $72,835 |
| IsentressRaltegravir Potassium | 38 | $71,557 |
| TivicayDolutegravir Sodium | 25 | $61,393 |
| Efavirenz-Emtric-Tenofov DisopEfavirenz/Emtricit/Tenofovr Df | 51 | $28,493 |
| PrezcobixDarunavir/Cobicistat | 11 | $27,278 |
| Etravirine | 21 | $20,763 |
| EvotazAtazanavir Sulfate/Cobicistat | 11 | $17,757 |
| Lopinavir-RitonavirLopinavir/Ritonavir | 11 | $9,121 |
| CeftriaxoneCeftriaxone Sodium | 25 | $5,481 |
| Vancomycin Hcl | 35 | $3,342 |
| Ampicillin-SulbactamAmpicillin Sod/Sulbactam Sod | 24 | $3,126 |
| Cefazolin Sodium | 50 | $2,398 |
Paid to pharmacies, not to this prescriber.
Other infectious disease in Olympia
- April FergusonOlympia$8K
- Francis RiedoKirkland$183K
- Warren DingesSeattle$173K
- Paul DrainSeattle$149K
- Corey CasperSeattle$115K
- Anna WaldSeattle$103K
- Jim BoonyaratanakornkitSeattle$62K
- Michael BoeckhSeattle$59K
- Jason GoldmanSeattle$58K
- Connie CelumSeattle$57K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.